NASDAQ:ENTA
Enanta Pharmaceuticals Stock News
$15.17
+1.26 (+9.06%)
At Close: May 03, 2024
Is a Surprise Coming for Enanta Pharmaceuticals (ENTA) This Earnings Season?
01:52pm, Friday, 19'th Nov 2021 Zacks Investment Research
Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Enanta Pharmaceuticals to Participate in December Investor Conferences
12:00pm, Friday, 19'th Nov 2021 Enanta PharmaceuticalsIs a Surprise Coming for Enanta Pharmaceuticals (ENTA) This Earnings Season?
09:59am, Friday, 19'th Nov 2021
Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Enanta Pharmaceuticals to Participate in December Investor Conferences
07:00am, Friday, 19'th Nov 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Participate in December Investor Conferences
Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program
09:01pm, Thursday, 18'th Nov 2021 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus Program
First Manhattan Co Buys IAC/InterActiveCorp, Enanta Pharmaceuticals Inc, Regenxbio Inc, Sells ...
03:38am, Wednesday, 17'th Nov 2021 GuruFocus
Related Stocks: IAC , ENTA , RGNX , IVV , WH , EOLS , IMCR , FCOB , MRSN , IMUX , BKCC , NEXI , HUM , GRA , ASND , NWHM , MUDS , BPY ,
Enanta Pharmaceuticals to Host Conference Call on November 22 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021
09:01pm, Monday, 15'th Nov 2021 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta to Host Conference Call on November 22 to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
08:00pm, Monday, 15'th Nov 2021 Zacks Investment Research
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
04:11pm, Monday, 15'th Nov 2021
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Explosive Biotech Stocks -- Could They Shoot Even Higher?
06:22am, Wednesday, 03'rd Nov 2021
These biotech stocks have recently been responsible for a slew of rocketship emojis.
4 Small Drug Stocks That Hold Promise Despite Industry Challenges
09:05am, Wednesday, 27'th Oct 2021
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry players' third-quarter results. XNCR, ENTA, CPRX and MTEM may prove to be good additions to one's portfolio.
Enanta Plans To Start Human Trials For Its COVID-19 Candidate In 2022
10:42am, Tuesday, 19'th Oct 2021
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has reported new preclinical data for EDP-235, its recently announced lead oral protease inhibitor for COVID-19. The data were presented at the Internati
Enanta Pharmaceuticals (ENTA) Moves 10.6% Higher: Will This Strength Last?
09:34am, Friday, 08'th Oct 2021
Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be m
WATERTOWN, Mass.--(BUSINESS WIRE)--New Preclinical Data for EDP-235, Enanta's Oral Protease Inhibitor for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference
Enanta To Discontinue Internal Development Of NASH Candidates
04:29pm, Monday, 04'th Oct 2021
After looking at interim phase 2b data, Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has decided to stop the monotherapy trial of EDP-305 for non-alcoholic steatohepatitis (NASH). Instead, Enanta now
